CARsgen Therapeutics Initiates Trial for Universal CAR-T Therapy KJ-C2219 in China
China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the initiation of an investigator-initiated-trial (ITT)...
Clinical trial approval / initiation
Hinova Pharmaceuticals’ HP568 Earns FDA Clinical Trial Approval for ER+/HER2- Breast Cancer
Chengdu-based biotech Hinova Pharmaceuticals Inc., (SHA: 688302) has announced that it has received clinical trial...
CSPC Pharmaceutical Group Receives NMPA Approval for SYH9016 Clinical Study in Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
HitGen Inc. Initiates Phase II Clinical Trial for HG146 in Adenoid Cystic Carcinoma
China-based HitGen Inc. (SHA: 688222) has announced the commencement of the first patient enrollment in...
Hinova Pharmaceuticals Enrolls First Patient in Phase II Study for HP518 in mCRPC
China-based biopharma Hinova Pharmaceuticals has announced the enrollment of the first patient in an open,...
China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval
On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...
Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval
China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...
Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...
Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial
China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...
ETERN Therapeutics’ YAP/TEAD Inhibitor ETS-006 Wins FDA Clinical Approval for Advanced Solid Tumors
China-based biopharmaceutical company ETERN Therapeutics has announced that it has received clinical approval from the...
Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101
Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical...
Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study
Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval to Test SHR-1681 in Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from...
CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...